<SEC-DOCUMENT>0001193125-15-004452.txt : 20150108
<SEC-HEADER>0001193125-15-004452.hdr.sgml : 20150108
<ACCEPTANCE-DATETIME>20150108074230
ACCESSION NUMBER:		0001193125-15-004452
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150108
DATE AS OF CHANGE:		20150108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		15514866

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d846737d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;8, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 250-0111 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015, Repligen Corporation announced
its preliminary financial results for the year ended December 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <I>Exhibits</I>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated January 8, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: January&nbsp;8, 2015</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walter C. Herlihy</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Walter C. Herlihy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated January 8, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d846737dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g846737ex99_1pg001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">41 Seyon Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building #1, Suite 100</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham,&nbsp;Massachusetts&nbsp;02453</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (781)
250-0111</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telefax: (781) 250-0115</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Receives Milestone Payment from Pfizer </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Reports Preliminary Revenue Results for 2014 and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Provides Initial Revenue Guidance for 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA </B>&#150;<B> January&nbsp;8, 2015</B> &#150; Repligen Corporation (NASDAQ:RGEN) announced today that on December&nbsp;30, 2014, it received a
$1 million milestone payment from Pfizer, Inc. under the terms of the companies&#146; exclusive worldwide licensing agreement (the &#147;Agreement&#148;) for the development of compounds to potentially treat spinal muscular atrophy (SMA), a
neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in
additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Revenue
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December&nbsp;31, 2014. This total
revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic programs and product revenue of $60-$60.5 million, an increase from our previous product revenue guidance of $58-$60 million. Product revenue reflects
sales growth of 26%-27%, driven by strength in sales of products that we sell directly to end users including partial year sales of the Alternating Tangential Flow System (the &#147;ATF System&#148;), the most recent addition to Repligen&#146;s
proprietary product portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2015 Revenue Forecast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2015, Repligen currently projects product revenue in the range of $69-$72 million, reflecting 15%-20% sales growth compared to 2014, which included only
partial year sales of the ATF System. Gross margin on product sales is expected to be greater than 55% in 2015. These projections do not include the impact on product revenue or gross margin of potential acquisitions and/or fluctuations in currency
exchange rates during 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Earnings Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen plans to announce complete financial results for fourth quarter and year ended December&nbsp;31, 2014 in early March, and will hold its earnings
conference call at that time. The preliminary, unaudited results reported in this press release could change as a result of further review by Repligen and its independent auditors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- more - </I></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the
process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media
that is used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In
addition, we developed and market an innovative line of &#147;ready-to-use&#148; chromatography columns under our OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand that we deliver pre-packed with our customers&#146; choice of
purification media. Repligen&#146;s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of
1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, constitute forward-looking statements, including,
without limitation, express or implied statements or guidance regarding future financial performance and position, including cash and investment position, our strategic decision to focus on the growth of our bioprocessing business, the future demand
for our bioprocessing, growth factor, ATF and chromatography products, plans and objectives for future operations, plans and objectives for product development and acquisitions, our market share and product sales and other statements identified by
words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business, including as a result
of acquisition, commercialization or partnership opportunities; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows,
results of operations and financial condition; the impact of the expiration on December&nbsp;31, 2013 of Bristol-Myers Squibb royalty payments from U.S. sales of Orencia<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the success of
current and future collaborative or supply relationships, including our agreements with Pfizer, BioMarin Pharmaceuticals Inc. [and Innovate Biopharmaceuticals Inc.]; our ability to compete with larger, better financed bioprocessing, pharmaceutical
and biotechnology companies; our compliance with all Food and Drug Administration and EMEA regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual
property rights; our limited sales capabilities; our volatile stock price; and other risks detailed in Repligen&#146;s Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically
files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management&#146;s current views and Repligen does
not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra S. Newman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 419-1881 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>snewman@repligen.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g846737ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g846737ex99_1pg001.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,J:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#0R`H5VEN9&]W<RDB('AM<$U-
M.DEN<W1A;F-E240](GAM<"YI:60Z13(Y1D(S-3`Y-CDR,3%%-#A!13-&-S$Y
M1$1$13(Y-S<B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z13(Y1D(S-3$Y
M-CDR,3%%-#A!13-&-S$Y1$1$13(Y-S<B/B`\>&UP34TZ1&5R:79E9$9R;VT@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#I%,CE&0C,T13DV.3(Q,44T.$%%
M,T8W,3E$1$1%,CDW-R(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#I%,CE&
M0C,T1CDV.3(Q,44T.$%%,T8W,3E$1$1%,CDW-R(O/B`\+W)D9CI$97-C<FEP
M=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB
M<B(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!
M`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`"0`D`,!$0`"$0$#$0'_Q`!O```"
M`@("`P``````````````"0@*!@<!`P($!0$!`````````````````````!``
M``8"`00"`00"`04``````@,$!08'`0@)`!$2"A,5%"$B%A<D&3%!,C0G&!$!
M`````````````````````/_:``P#`0`"$0,1`#\`M4\S7(0^<8F@%J[80Z.1
M28V''7^NHC7D2F_VG\7?Y)-9NS,ZM.[`9'1E>#26Z)B<UX0IU)8\C28[YR#R
MQD*CM?>T_P`W=M15NG=5<5D*LV#NYBTEIF5?4#MQ,XJZ&MJPYN<2FZ0QR8.3
M0M,0."8P@X)1PLE'%B`+L(.<8#-:6]R'8NO+W8:RY#M%(]5<45/38@FZV")[
M/K^RZX974P@O$G4UO:1DA52@AN+&)0-)A0V&J",9^$>1AP$P+]C2ZMSZUMKV
MSK"'!I>&]&ZM:],+S3+FYP3EJT2Q./\`3S(4IC@C!G_J$6.@^AT!T!T!T%=;
MV%N:6R.'RN-;W*F*_JVRK)O>;3A"8QVD*4&M3;!X`Q,ZA[=D:2)2&-N7V`WZ
M6-9)9AIXB/CR;CP$+L(`;-W8Y,-N=6.(FB=U8KKI'K2VZN"-Z\*%M)Q:'VE+
M(.P26UXP3-YH08RQ=>?.R&6)1](M(+.4+BP@78)"::+(PEF!+WC%VNOC:#0.
MK]L-RJ^ANNMA3-NL*5RN&I4,IA##`X1%IA)V=H=I(GLMU6/+")3&(\%U5&K%
M`""TYX3,>)?Z]`H&:<]^U6XEK3:G.#;1)5N2R5N]F1R;[<W$\**[UH1OA(?D
M.;XV<N=83]\48FS@Y,:I?6Y<K*S\Q#<>E$6H,#0EJ<TG.-QFG1^Q^5;C;IR2
M:L.4A0L<DN/4N6J#ED,&^+0$-XE^5-C66T)U)0C<)TJ5Z(CY#JK\22G``QA[
MA;%H^Z*YV,IZL[XJ*0$RJL;=A,>L"#OY)9A'V,=DS:0YMXU*0[`5"!P)*/\`
MB4IC<!.2J`#*,"$8!8P&T^@.@.@.@H[>[A?F&'7#3#69&MR%39EPSFY7I&4,
M6,Y:ZCB*:(M'Y0<![9(5N5MG"+QG.,"&DSG&,Y#WP&?\5WL.<-&C_';J/JY)
M;RGR*:533K&DL%"V4':RQ"GLR3'K9M9*9&O1QLY"XDE3N2.``*2S!%*,8P9@
M7B+H$T[N+)I[4?*U6";1NG9Q&]9Z5@<.J:Q=B9S&R68J/PPR8268RF>S$PE4
MI0MRHXEZ5)(K&\JSG1R,2B-R`D)R@*0'W<[_`#0W?I7/Z+XJ.,9B*D.X]DQ^
M`Q8V2!:4$P?*P;I<))%*HA$,87DH^.N%J3,HL"L:IV*.1-+88G/R08-:`Y&"
M1-_M7O9,XNJ-:>0BU^3V?34E'(8@T63%H1L':,O*KAPESB0GCY;Y`IO'D-22
MB-8DIQ+:I+1I5*8"@\H`23DHA&`!_P!)^9BTK']9"9\D7W:>N=F7*L7.H1/\
M23`:PM][FVR51`9K$$1V5)#>H5Y48DA!`<&%(AB$6'&0$]`D#C6E?LN\LVG4
ML;:/VX555622U),K>=K[GGSY&[#LIS21R.-R.G:G>X;!)%*8["H6M1&JW%>W
M$H\*G-T-(,7FX3&(BP\>$'DOY.]4>8)NXM=[+ALBZ6&5SV:TC,XW;,[<;7=Z
M\L5DCS])XE-J\L&0*W*0'1Y]4MY(!$?EY0+&MS"H^`)Y160AT^T.XK=TN</1
M;0MB..5)&5BHZKUZ5.;D8T$NV3M@*J1*<%?($!`@03+"<//[<Y`7C.<]L![`
MRCVL.3O:+0QWT?UYT@N.2T=+I:P6'+YG_"$C"<M7Q%M4Q"#UBPA(>6AU**1#
M<T[UX!*`#(AIPX[]@]N@S7V!;NV-0ZK<9_#]$+%?G?9_D.<ZCJ6^K(5'!!(7
MJ,L!-?Q"=*I`)H`W$DH[+LV4!5N>"/B3G-;4O2"!^.>,/063Z6I_5OB^TS:H
M%%01ZG=;]9:S7ODJE#@4!.64TQEI,=YS9<V6(4PU+Q)7XY,H<W17\9AZE2:+
MP#_V`P"O=FN8K@/VXH*U=:[IWMJ1YJVY(DNALR0-W\^;G,38M&2>!4U./\'/
M$VN[:M3%*4B@(!"(4%`,#CR#CH-LJ]H-#^&SAV@-TTX^R6Q=38!`40]8F]1(
MG%\F%TN5NOSU,*\BC"^R%N1N(R9(YR,X\"@U'XM;"G,/P2,I+X9!><8TG]@O
MD(@B#8J].3\WC97SUO(F-9:CZ^5!]F"LV!S`:YQEBMB8`F,+E:F392*"/LD:
MM6]C(SG)9OQ&A&C("0_`;O3M_=$CWIT/W^E+#8NT?'O;K/!G*V6-$W-H;+@D
MD,E#8SNJXAM;F5,XJ4+A"SCRG+*)&>L;G-)A25A46<8:"R=!MT.:/EONKD7A
M&M6QL<H35YCV?DK##]K9E7$0G+M2E7-3U+4\0I77V`)&:-$3"PI9&EJ%R>WR
M0N"OZ=`E39*,(5+"A'ADM+6IRE<8'.%J/Q][!;X2GD(H#=*#/\G&LL:)A:)7
M$!$MUC=W9L)4.DJ=8LKB\A@F#A%IGA0TK&=2:`28D\!9A(*;]E9:NWD]@/5;
M2!F.&N;XNVZS:_K4"7R-_!?[RGH9Q+'$T))P\@$5#9VU".SV+$`I)C.?T#Y=
M!;]>/7=X436AS*7:%50@0B;U85:])(K.;5:)-^./YU:=Q2SLI4B/3E=QA-`,
M(P9QY8SWQT%,3U%&%R4\QE[FU`ZR-+1T7H6[EJ]&>ZJ#DKQ#CK+A##6B>1?"
M%.A=G4DQQ(4E&#*"+S)-&#`<>6.@C_=E+PG=_P!G':ZG-E]G9+JBDD^RERQF
M(7:WN#8R/+`ZULQ*&BFX\WOCXX,[>S8?X]%T+<WG"4%".,,(**R(PX&!!/[>
M7B?XGM5E3!5.XG/OLZX+)RF&\)*Y(:G:^S!)6E6E$C<9)%X"HGQ;``U>,.6\
M3D2G$J-*'E-YY),R`,M]@NJJXXT.##CWXY*;F<QET=LV]I9<)DFL"-CA4ZE,
M79T\JLAR#*XB%,W&QU<@D]VL9&42LD*DC#<`!P<'@'XA86X6=T=!-?N$'4F7
MN6Q5,5_!J@HH([A+>9M&V]\BUHEN#N^VFT.D5*69DATG=)TXK3D*$M(8O=0*
MDXTQ9WY!/F%9C@WBDLY8?8BV!Y-@19W9Z0J.<V9=0%;B1DHM$MF;(^59KW7[
M@J3^:44K*B1N750``A`[,1^<Y[#!Y![NC/;D%]OJZ[F,&8_0ZBK:OV=)E.1?
M.G_C.O$3%KU6+@3D1(RRTH9/EB5%8#X]A9P+`A9_40<\I6<<@?MEZWZVEC&^
MQ"F)_K'5;JB+$(Y,*,5TBQLI;J;!0BAE!$00_O"91^F<9RGS@0L>/[09=STR
M5!J_SU<*^Z-T8PSZSM*<BN'R<N(3<QJ'21HL64F2%[>U.2#TK:5'6BU6EW$/
M/8TQ,WGC!_X^1!"XW*(K6UUUZY1:8,,-M.K;#8`$.K"^H&>8P:;1=W(*4EE+
M4"PMP8Y"PNB88!XP,)J<\O.,_N#G'04$O9GFO&/#H]`.-_0_634M/N!:=O5^
MALN94?3E7LSS3C+AZP0P5XKF4-CB=8U6%8,K.1A.;"5/Y*9G2GX6%`"L3X&$
MK?9.IIC;!<`?'N]V"]U'K&ZW4R51,[&9#P(1Q$B`-]"5!%Y6E<5V!M#:^Q:)
M3!X/1J581%IQ'C.'W+`9W"=EB<`T8J:#2ZSK,YS>8.#5_!&%SE,QF$FW,^L8
MH['V=,8M<G5T<%,=`40F2IRLBSG/[A9[!#C(LXQD-,<?,*TUT>XP>3GE/U$O
M[;O8-#=]33^0F7!N&@1M\\F4[I&.6,TQMXCB]5&XQ()"@D=D3C*`YQ7F*!*5
MZ+)98@B*'Y!.WU?Z#Q1'#3K*I5H\))#>*VP;_D8\E#+-6F3Z7."*)KCA&!",
MX:BN(ZR>(_\`@0,!\<Y#VSD(<5R'.VOMKW1+AF?9Q'C?TC9H*RJ!9$8C;K`L
M=K;<JTR8`L&%EKAI[TD11@L>`LY;\X[Y\,=PGLE]?_5#/*(/E??;5V`E-\?V
M8KM)-!'MYK@RI4;[B'FPJ/(B&I-6R>6_61%KPG,;\9>,G@4(R1C,'C`@B!VL
MQC26:1"50Y:L7MZ*61M\C2M>U'`3N:%*^MBIK4+&X\PHXLA>F*59&2,0!A"8
M'&<ASC';H$I<5G`;K'Q&VO8]L:^7)L+.%]I0$BOY1';;<ZP=F+*%$_H)"W.B
M`R)5C#WI(Z(5*,PO'^6).84H'\A0A!+$`-?\G_K;:'\G=K+M@Y8ZV;1%_O3>
MV-TML*HG"/Y;;``QMI;.R+IW#92R/+8YO+6U)4Z4"Y":VJSDJ<LH\P[!962P
MPCC\]6_C<T1LB.W6O(L39ZWH>X)'J&OMZ+H\IAT+D*`P@]#(HU748861D->V
M]65\R4]W,=Q(SL`-3_$>6`W`5V/:9=UVXG-;H9H?'#35H&6/4U7JM(1D!XD,
MTV7MX`7H>2`%G"+R"$(F!0/S"+/Q_N\?'MY`Y*\_3DXW[<O=^M>)V;?]'P.5
M/JJ0O-(5PN@9D1:52X_"E6VP!VDT0>W:)1XT\1@@(CL.($H3/C3"))`66`+%
M&G&CVM6@M%->O.J==H:P@+>-0X+#TQIKK*)1*%J4A*OFDRDCKE4XR>4K0)BL
M"/5"$644460264F**)`"^.,/@=U8XL+MN#8&GK.ONTK(NB)'0V2.=TOL#>2T
M#8OEB.:/9[3_`!"OH:JPO?7QM2C4F*#5&!8(#V#C.19R'70G`UJU0G)9/N4M
M!:=_3O8">RNWYB='9R^5^KKB/O%R$.K<]886YGKQFDI*1@87I0WM99SH=\"4
M00CR;D.,]`PW=31_6KD%HM]UWVFKQ)8%=NZQ,\(,@5*&B30^4-Y2@IJF$)DJ
M$1;E&Y,V%JS2P'DBR`Y.<:F4%G)CCB3`0%#O50I^"8Q#(OR8\FT=H+&1EYI&
M+WFT1AB,0'*<C4M!I[/&$[!EL4H\_`,(68!F>^1>??\`3H&)QW@*XTX1$-98
M57U/NL#;=7-C(?M/'')AD7Y<HLVW846`+6Y7=*I,W2%^L%G,,+",2+)Z0I/V
MR!)^,4(98@E;R'<<6L')W0INO^T,9=')@1/9$KA<OB;F6PS^N9>F1JV\J20Y
M\.1N*4A2:WKCDZE*K2JT"PDSQ.('D!8@`GJ(^L#1;F;&8SM'OKR&;A41!ER!
M3$=;[=OA>GJ,M(T*2U#2V2%J9R0KG!*@P7X%_6G,V0`SX@\`XP'H'#[>\>]*
M[;Z0R?0$U?):&H221Z"PXM!0Q$3BKA'(77TDCLD98E&$[S&9%'6EC.-C"9,>
M5A`+R2>98<AR+(N@DW1M01#7REJDH>ORE1,&IBM815D0`O&F,<,QN!1MMB[,
M:Y')$R)*>Y'H&L`U!A9)03#A"%@(>_;`0ZT_XSZ6TUV.W8VFA4PLN<6IO78S
M=8=H++"<(PL;8OEH=YD[M<4K]+'(M'#6V,(C)H:4$"TU>J$2E38$=G)><B!C
M'0'0'0'0'05V;*_T`?[D&'^T?IO]N?\`85:?QW[_`/\`JO\`/_GG];Q_^K_K
INW_H#M_`OK_PO'_#^7Q\O\ORZ"Q-T!T!T!T!T!T!T!T!T!T!T!T'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
